![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 39, 30605-30609, September 29, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the CNRS-Unité Mixte de Recherche 8526, Institut
de Biologie de Lille/Institut Pasteur de Lille, 59021 Lille Cedex and
the § CNRS-UMR8576, Université des Sciences et
Technologies de Lille, 59655, Villeneuve d'Ascq Cedex, France
Received for publication, May 15, 2000, and in revised form, July 5, 2000
The addition of N-linked
oligosaccharides to Asn-X-(Ser/Thr) sites is catalyzed by
the oligosaccharyltransferase, an enzyme closely associated with the
translocon and generally thought to have access only to nascent chains
as they emerge from the ribosome. However, the presence of the sequon
does not automatically ensure core glycosylation because many proteins
contain sequons that remain either nonglycosylated or glycosylated to a
variable extent. In this study, hepatitis C virus (HCV) envelope
protein E1 was used as a model to study the efficiency of
N-glycosylation. HCV envelope proteins, E1 and E2, were
released from a polyprotein precursor after cleavage by host signal
peptidase(s). When expressed alone, E1 was not efficiently
glycosylated. However, E1 glycosylation was improved when expressed as
a polyprotein including full-length or truncated forms of E2. These
data indicate that glycosylation of E1 is dependent on the presence of
polypeptide sequences located downstream of E1 on HCV polyprotein.
Proteins that are transported and sorted by the secretory pathway
begin their journey at the endoplasmic reticulum
(ER)1 membrane. It is here
that nascent secretory and membrane proteins are translocated across or
integrated into the membrane. However, before moving to the final
destination, these proteins have to be appropriately modified, folded,
and assembled. Among the modifications affecting proteins targeted to
the secretory pathway of eukaryotic cells, N-linked
glycosylation is often observed (1). This modification plays an
important role in regulating the activity, stability, and antigenicity
of mature proteins (2). In addition, N-linked glycosylation
allows newly synthesized glycoproteins to interact with a lectin-based
chaperone system in the ER, which plays a major role in protein folding
and quality control (3, 4).
The addition of N-linked oligosaccharides is catalyzed by
the oligosaccharyltransferase, an enzyme closely associated with the translocon and generally thought to have access only to nascent chains as they emerge from the ribosome (5). It has been shown in a
cell-free translation system that oligosaccharide transfer only occurs
when 12-14 amino acids C-terminal to a sequon have been translocated
into the ER lumen (6). This suggests that the active site of the
oligosaccharyltransferase and dolichol oligosaccharide donor, which are
tethered to the luminal surface (7, 8) are projected 30-40 Å into the
ER lumen (6). Core glycosylation determines the number of individual
oligosaccharides attached to a given polypeptide and involves the
transfer of a presynthesized
Glc3Man9GlcNAc2 unit from a
membrane-associated donor, oligosaccharide-pyrophosphodolichol (9), to
asparagine residues in the tripeptide acceptor sequon
Asn-X-(Ser/Thr) (10), where X is any amino acid
except Pro (11-13). Although the sequon is essential for core
glycosylation, it is observed that all potential glycosylation sites
are not utilized (14), and some sequons are inefficiently
glycosylated (15). Recent studies have demonstrated that the amino acid
present at the X position of the sequon may modulate the
efficiency of core glycosylation (16). In addition, inhibition of
disulfide bond formation may increase the level of modification of a
naturally occurring glycosylation sequon, suggesting that there may be
a link between folding and utilization of glycosylation sequons
in vivo (17, 18). In a study using carboxypeptidase Y in
Saccharomyces cerevisiae as a model system, the introduction
of new sites for N-glycosylation at positions buried in a
folded protein structure did not necessarily lead to glycosylation of
these sites, indicating that folding and glycosylation can compete
in vivo and that glycosylation does not necessarily precede
folding (19).
The maturation of viral proteins in infected cells involves mostly the
host cell metabolic pathway, including localization mechanisms, folding
proteins, and enzymes that modify the primary translation product. For
this reason, viral envelope proteins have often been used as tools for
cell biology studies. In this work, we used hepatitis C virus (HCV)
envelope protein E1 as a model to study N-glycosylation in a
cell culture system. The HCV genome encodes two envelope proteins, E1
and E2, which form a noncovalent heterodimer (20). These two envelope
proteins are released from HCV polyprotein precursor after cleavage by
host signal peptidase(s) (21). They are transmembrane proteins with a
large N-terminal ectodomain and a C-terminal hydrophobic anchor, and
they are heavily modified by N-linked glycosylation (20). E1
has been shown to be glycosylated at positions 196, 209, 234, and 305 (positions on the polyprotein) (22). Here, we show that E1 was not
efficiently glycosylated when expressed alone. However, glycosylation
of E1 was improved when expressed as a polyprotein with the full-length
or a truncated form of E2, indicating that glycosylation of E1 is
dependent on the presence of polypeptide sequences located downstream
of E1 on HCV polyprotein.
Cell Culture--
The HepG2 cell line was obtained from the
American Type Culture Collection, Manassas, VA. Cell monolayers were
grown in Dulbecco's modified essential medium (Life Technologies,
Inc.) supplemented with 10% fetal bovine serum.
Generation and Growth of Viruses--
Plasmids expressing
proteins of interest were constructed as described previously (22).
Vaccinia virus recombinants were generated by homologous recombination
essentially as described previously (23). The following vaccinia virus
recombinants have been described previously: vTF7-3 (expressing the T7
DNA-dependent RNA polymerase) (24), vaccinia viruses
expressing E1 or glycosylation mutants of E1 (N1, N2, N3, N4, N2-3,
N1-2-3 and N1-2-3-4) (22), E1E2-524 (expressing the signal sequence of
E1, E1 and a truncated form of E2 ending at residue 524) (25), E2E1 and
E2 (26), E1E2-715 and E1E2-661 (27).
Metabolic Labeling, Immunoprecipitation, and Endoglycosidase
Digestions--
Cells expressing HCV proteins were metabolically
labeled with 35S-protein labeling mix (100 µCi/ml, NEN
Life Science Products) as described previously (28). Cells were lysed
with 0.5% igepal CA-630 in TBS (50 mM Tris-Cl, pH 7.5, 150 mM NaCl). Immunoprecipitations were carried out as
described previously (29). Gel autoradiographs were exposed in the
linear range and analyzed by densitometric scanning. Phosphor imaging
quantifications were also performed.
Western Blotting--
Proteins bound to nitrocellulose membranes
(Hybond-C extra, Amersham Pharmacia Biotech) were revealed by enhanced
chemiluminescence detection (ECL, Amersham Pharmacia Biotech) as
recommended by the manufacturer. Briefly, after separation by SDS-PAGE
under reducing conditions, proteins were transferred to nitrocellulose membranes by using a trans-blot apparatus (Bio-Rad) and detected with
specific mab (A4, see Ref. 28, dilution 1:1000) followed by rabbit
anti-mouse immunoglobulin conjugated to peroxidase (dilution 1:1000, DAKO).
E1 Expressed Alone Is Not Efficiently Glycosylated--
Some RNA
viruses synthesize their polypeptides as a polyprotein precursor that
is cleaved co- or post-translationally by viral and/or host proteases.
The fact that the envelope proteins of this type of virus are
translated from a single coding region implies that internal signal
peptides must be used. HCV envelope protein E1 has its signal sequence
located downstream of the mature form of the capsid protein (C) (21)
(Fig. 1, top). In addition, a
hydrophobic sequence present in the second half of the transmembrane domain of E1 is the signal sequence for the other envelope protein E2
located immediately downstream of E1 on the polyprotein. Previous work
has shown that the expression of E1 alone with its signal sequence
leads to its translocation in the ER lumen and anchorage of its
C-terminal hydrophobic sequence in the ER membrane (30). However, E1 is
often resolved as a multiband protein when analyzed by SDS-PAGE,
suggesting that different glycoforms of this protein might exist
(31-33). To confirm that the isoforms of E1 represent proteins that
differ in their degree of glycosylation, E1 and glycosylation mutants
were expressed in HepG2 cells by vaccinia virus recombinants, and their
electrophoretic mobilities were compared after separation by SDS-PAGE
followed by Western blotting. As shown in Fig.
2a, the bands detected for
wild-type E1 comigrated with the highest molecular-weight bands of
mutants lacking one (E1-N2), two
(E1-N2-3) and three
(E1-N1-2-3) glycans. In
addition, when deglycosylated by
endo-
Previous data obtained from our laboratory have indicated that among
the four glycosylation sites of E1, only site 4 is less efficiently
glycosylated in vitro (22). However, because folding and
glycosylation can compete in vivo (19), the glycosylation observed in vitro does not necessarily reflect the situation
occurring in vivo. To analyze whether some glycosylation
sites of E1 were inefficiently glycosylated in vivo, mutants
of E1 lacking one glycan at position Asn-196 (N1), Asn-209 (N2),
Asn-234 (N3), or Asn-305 (N4) were expressed in HepG2 cells,
pulse-labeled for 10 min, and analyzed by SDS-PAGE. A quantitative
analysis revealed the following percentages of underglycosylated E1
(Fig. 3): wild-type E1 (51%), N1 (36%),
N2 (52%), N3 (57%), and N4 (37%). Although the difference in the
level of glycosylation of these mutants was not dramatic, it was
repeatedly observed. Because there is a higher percentage of fully
glycosylated molecules for proteins having a mutation at site 1 or 4, it is very likely that these two sites are less efficiently
glycosylated in wild type E1.
Coexpression of E1 and E2 in Cis Improves the Efficiency of
Glycosylation of E1--
We have shown that E1 needs to be coexpressed
with E2 to efficiently form its intramolecular disulfide bonds,
indicating that the folding of E1 is assisted by E2 (27, 34). Although
E2 is located immediately downstream of E1 on the HCV polyprotein, we
wanted to determine whether the coexpression of the two envelope proteins would have some effect on the efficiency of E1 glycosylation. To answer this question, the electrophoretic mobility of E1 coexpressed with E2 was analyzed by SDS-PAGE followed by Western blotting and
compared with E1 expressed by itself. Expression of E2 in cells
infected with vaccinia virus recombinants expressing E2E1, E1E2, or
E1+E2 was confirmed by Western blotting with an anti-E2 mab (data not
shown). To be sure that all the cells would express both E1 and E2 when
produced by different vaccinia virus recombinants, a multiplicity of
infection of 5 pfu/cell was used for each virus. As shown in Fig.
4a, the ratio of fully
glycosylated E1 was higher when the two envelope proteins were
coexpressed (E1E2; approximately 75% of total E1), whereas only
approximately 50% of E1 expressed alone (E1) was glycosylated at all
four sites. Similar results were obtained by using Sindbis virus
recombinants (data not shown), indicating that this observation is
independent of the expression vector. It is worth noting that when
analyzed in pulse-chase experiments, the intensity of E1 coexpressed
with E2 was lower during the pulse, and a smear was observed above the
E1 band (Fig. 4b, compare E1 and
E1E2). This suggests that synthesis of the polyprotein is not terminated at this time point and that cleavage between E1 and E2
is not yet complete. The difference in the efficiency of glycosylation
of E1 expressed in the presence or absence of E2 indicates that the
presence of E2 improves the efficiency of glycosylation of E1. When
HepG2 cells were coinfected by vaccinia virus recombinants expressing
E1 and E2 separately (E1+E2), no change in the glycosylation profile of
E1 was observed (Fig. 4a, compare E1 and
E1+E2), indicating that E1 and E2 need to be expressed from
the same transcript to increase the efficiency of glycosylation of E1.
However, when the positions of E1 and E2 were inverted on the
polyprotein (E2E1), instead of observing a relative increase in the
intensity of the fully glycosylated E1, a slight decrease was
repeatedly detected (Fig. 4a, compare E2E1 and
E1), indicating that the position of E1 and E2 on the
polyprotein is important for efficient glycosylation of E1. Altogether,
these data indicate that coexpression of E1 and E2 in cis, with E2
downstream of E1, improves the efficiency of glycosylation of E1.
The N Terminus of E2 on HCV Polyprotein Is Sufficient to Improve
the Efficiency of Glycosylation of E1--
To determine whether the
whole sequence of E2 is necessary to improve the efficiency of
glycosylation of E1, deletions were introduced in E2. As shown in Fig.
5a, C-terminal deletions of E2
ending at position 715 (E1E2-715), 661 (E1E2-661), and 524 (E1E2-524) did not reduce
the efficiency of glycosylation of E1, indicating that the presence of
the N terminus of E2 is responsible for E2-dependent
glycosylation of E1. We also wondered whether the sequence necessary to
improve the glycosylation of E1 needs to be a specific one. We
therefore replaced the N terminus of E2 by a short amino acid sequence
corresponding to a Myc epitope (EQKLISEEDL) plus three Gly residues at
the junction with E1 (E1-Myc). The last residue at the C
terminus of E1 (Ala) was replaced by an Arg to avoid partial signal
sequence cleavage which would interfere with interpretation. Although
the effect was less dramatic, the presence of another sequence
downstream of E1 is sufficient to improve its glycosylation (Fig.
5b). Together, these data suggest that there is no
specificity in the sequence necessary for improvement of E1
glycosylation.
The E2 Sequences Involved in Improvement of Glycosylation and
Assisted Folding of E1 Are Distinct--
It has been shown that E1
needs to be coexpressed with E2 to fold properly (27), and here we show
that coexpression of E1 and E2 from the same polyprotein improves the
efficiency of glycosylation of E1. We therefore wanted to know whether
these two functions of E2 are linked. Because the presence of a
truncated form of E2 on HCV polyprotein is sufficient to improve the
glycosylation of E1, we analyzed whether a truncated form of E2 also
improves the folding of E1. For this purpose, we monitored disulfide
bond formation by SDS-PAGE under nonreducing conditions as described previously (29). This method takes advantage of an increase in mobility
as a protein acquires a compact conformation stabilized by the
formation of intramolecular disulfide bonds. An oxidized form of E1,
which appeared slowly, was clearly detected in the context of E1E2
(Fig. 6) as previously observed (29).
However, the intensity of the oxidized form of E1 was lower when the
polyprotein was truncated at the C terminus of E2 (Fig. 6,
E1E2-661) or in the absence of E2 (Fig. 6, E1).
Quantitative analyses showed approximately a 50% reduction in the
formation of oxidized E1 when E2 was truncated. It has to be noted that
part of E1, when separated under nonreducing conditions, formed high
molecular weight aggregates. This explains, especially for
E1E2-661 and E1, the lower intensity of the bands observed
during the chase (data not shown). Together, these data show that E2
needs its transmembrane domain to improve the folding of E1, and this
indicates that E2-dependent glycosylation of E1 and
assisted folding are distinct functions.
The modification of Asn-X-(Ser/Thr) sequences with
oligosaccharides is one of the ubiquitous features of the eukaryotic
secretory pathway. The number and position of oligosaccharides added to a protein by the enzyme oligosaccharyltransferase can influence its
expression and function. However, it remains poorly understood why some
sequons are glycosylated to a variable extent. Here, we report that a
sequence located far downstream of the glycosylation sites of HCV
envelope protein E1 modulates the efficiency of glycosylation of these sites.
HCV envelope protein E1 is not efficiently glycosylated when expressed
in the absence of E2. Indeed, approximately 50% of E1 was partially
glycosylated when expressed in HepG2 cells by a vaccinia virus
recombinant. Residues like Trp, Leu, Asp, and Glu at position
X have been shown to be associated with less efficient core
glycosylation in a cell-free system (16). Indeed, large hydrophobic
amino acids may inhibit core glycosylation by producing an unfavorable
local conformation, and the charge of the X residue may
influence the ability of oligosaccharyltransferase to bind simultaneously to the sequon and the negatively charged
dolichol-PP-oligosaccharide precursor (13, 35). A Ser (N1 and N2), an
Ala (N3), and a Cys (N4) occupy the X positions in the
sequence of the E1 protein used in our study (22), and these residues
are usually associated with highly efficient core glycosylation.
However, the Cys residue is uncommon at the X position in
core-glycosylated sequons (36). This probably reflects the potential of
the Cys residues to participate in disulfide bonding (37, 38).
Therefore, one hypothesis to explain the lower efficiency of E1
glycosylation at site 4 is that in the absence of E2, the Cys residue
might be partially reactive to form disulfide bonds. More recently, it
has been shown that the residue in position Y can also
influence the efficiency of glycosylation in the sequon
Asn-X-Ser-Y (39), and the presence of an Ile at
position Y as seen at site 4, is not the most favorable residue for maximum efficiency of glycosylation. This might also explain why in vitro core glycosylation is partial at site 4 (22). Core glycosylation can also be influenced by the position of the sequon in a protein (6, 14, 40), and the location of site 1 of E1, five
residues from the N terminus, is not favorable for glycosylation.
However, when the efficiency of glycosylation of this site was studied
in a cell-free system, it was fully glycosylated (22), suggesting that
other factors probably involving folding (18, 19, 37) might play a role
in modulating the efficiency of its glycosylation.
Our data indicate that glycosylation of E1 is improved when expressed
as a polyprotein including full-length or truncated forms of E2,
indicating that glycosylation of E1 is dependent on the presence of a
polypeptide located downstream of E1 on HCV polyprotein. How can such a
sequence, which is rapidly cleaved from the polyprotein by signal
peptidase, improve the efficiency of glycosylation of E1? Recently, it
has been shown that some mutations of the MHC class II-associated
invariant chain (Ii) lead to a reduced interaction with the
ribosome-associated membrane protein 4 and inefficient N-glycosylation,
suggesting that glycosylation can be individually regulated by an
interaction with ribosome-associated membrane protein 4 (41). However,
this mechanism might be specific for Ii. In this model,
ribosome-associated membrane protein 4 is proposed to mediate a
translocational pause by interacting with a sequence of Ii immediately
downstream of the two glycosylation sites. In the case of E1, the
sequence responsible for improvement of glycosylation is located 188 and 79 residues downstream from sites N1 and N4, respectively. In
addition, there seems to be no specificity in the sequence involved in
assisting glycosylation. A study using rabies virus glycoprotein as a
model has shown that core glycosylation can be influenced by the
presence or absence of regions more than 68 amino acids C-terminal to a
specific glycosylation site (42). This is in agreement with recent data
showing that, in the absence of a stop transfer sequence between the
glycosylation acceptor sequon and the C terminus, the efficiency of
glycosylation increases as the stop codon is moved further away from
the sequon and plateaus at a distance of ~60 residues or more (43).
These data suggest that glycosylation is inefficient when chain
termination happens before the acceptor site reaches the
oligosaccharyltransferase active site. Indeed, in a nascent
polypeptide, the distance between the ribosomal peptidyl transferase
site, and the oligosaccharyltransferase active site has been estimated
to be ~65 residues (44). In the case of E1 expressed alone, the N4
site is located 79 residues from the stop codon, which had been
introduced at the C terminus of E1. However, the stop transfer sequence
of E1 was not deleted and the N1 site, which is also less efficiently
glycosylated is located 188 residues from the C terminus of E1. An
alternative explanation of E2-dependent glycosylation of E1
is that the folding of this protein might be different depending on
whether it is expressed alone or coexpressed with E2, and the folding
of E1 expressed alone might compete with its glycosylation. In
vitro studies have shown that the acceptor peptide probably has to
adopt a specific conformation, the Asn-X turn, to become
glycosylated (45). Formation of an alternative secondary structure
forced by a change in the folding pathway could disrupt such a
conformation. We have previously reported that E2 plays a role in the
assisted folding of E1, and this might be a way for E2 to improve the
efficiency of glycosylation of E1 (27, 34). However, we show in this work that E2-dependent glycosylation of E1 and
assisted-folding are not linked together. Alternatively, the presence
of E2 downstream of E1 on the polyprotein might impose a conformation
to E1 which is more favorable for N-glycosylation.
This conformation would be transient and only observed before cleavage,
and such a transient conformation would not be observed in the absence
of a sequence downstream of E1. Pulse-chase experiments suggest that
E1E2 polyprotein is not completely cleaved during the pulse (Fig.
4b). This slight delay in E1E2 cleavage might be necessary
for E2-dependent glycosylation of E1. We have
recently observed a conformational modification in the transmembrane
domain of E1 after cleavage between E1 and E2.2 Such a conformational
change might have some impact on the folding of the ectodomain of E1
and potentially on its glycosylation.
Because the glycosylation of a protein can influence its expression and
function, it is important to understand why some proteins are only
partially glycosylated. It has been shown that the type of amino acid
present at the X position of the sequon can modulate the
efficiency of core glycosylation in vitro (16), and in some instances, folding has been shown to compete with glycosylation (17-19). Control of glycosylation as described for E1 has never been
reported before and it is likely because of the constraints imposed by
the way HCV expresses its proteins. Whether it is unique to HCV
envelope proteins or it applies to other glycoproteins synthesized as
polyprotein precursors remains to be shown.
We thank Françoise Jacob-Dubuisson and
André Verbert for critical reading of the manuscript and
André Pillez and Sophana Ung for excellent technical assistance.
*
This work was supported by the CNRS, the Institut Pasteur de
Lille, a European Regional Development Fund (ERDF) and Grant 9736 from
the Association Pour la Recherche sur le Cancer.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Published, JBC Papers in Press, July 5, 2000, DOI 10.1074/jbc.M004326200
2
L. Cocquerel and J. Dubuisson, unpublished data.
The abbreviations used are:
ER, endoplasmic
reticulum;
HCV, hepatitis C virus;
mab, monoclonal antibody;
pfu, plaque-forming unit;
PAGE, polyacrylamide gel electrophoresis;
N1-N4, El protein glycosylation mutants.
Glycosylation of the Hepatitis C Virus Envelope Protein E1 Is
Dependent on the Presence of a Downstream Sequence on the Viral
Polyprotein*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-N-acetylglucosaminidase H (endo H) or
Peptide:N-glycosidase F (PNGase F), E1 was resolved
as a single fast migrating band (Fig. 2b), which comigrated
with E1 expressed in cells treated by tunicamycin, a drug that blocks core glycosylation of nascent glycoprotein precursors (data not shown).
The sensitivity of E1 to endo-
-N-acetylglucosaminidase H
treatment is caused by its retention in the ER through its
transmembrane domain (34). Altogether, these data confirm that
different glycoforms of E1 are produced when it is expressed in the
absence of E2.

View larger version (14K):
[in a new window]
Fig. 1.
Processing of the N-terminal region of HCV
polyprotein generating the envelope proteins E1 and E2, and schematic
representation of the proteins expressed in these studies. Signal
sequences and transmembrane domains are indicated by solid
boxes. The arrows indicate the sites that are cleaved
by a signal peptidase. The amino acid positions of the first residues
of E1, E2, and p7 are indicated above the arrows. The
N-linked glycosylation sites of E1 are indicated by
asterisks. These sites are located at amino acid positions
Asn-196 (N1), Asn-209 (N2), Asn-234
(N3), and Asn-305 (N4), respectively.
Numbers reported at the end of truncated E1E2 polyproteins
indicate the positions of the last residue of E2 present in the
truncated polyprotein.

View larger version (42K):
[in a new window]
Fig. 2.
Glycosylation of E1 expressed in the absence
of E2. HepG2 cells were coinfected with vTF7-3 and the appropriate
vaccinia virus recombinant at a multiplicity of 5 pfu/cell. Infected
cells were harvested at 7-h postinfection, the proteins were separated
by SDS-PAGE (13% acrylamide), and E1 was revealed by Western blotting
with the anti-E1 mab A4. The migration profile of E1 expressed in the
absence of E2 (E1wt) was compared with glycosylation mutants
of E1 lacking one (E1-N2), two
(E1-N2-3), three
(E1-N1-2-3) or 4 (E1-N1-2-3-4)
glycans (a), or to wild-type E1 digested by
Peptide:N-glycosidase F (PNGase F) or
endo-
-N-acetylglucosaminidase H (Endo
H)(b).

View larger version (28K):
[in a new window]
Fig. 3.
Glycosylation of E1 mutated at glycosylation
site N1, N2, N3, or N4. HepG2 cells were coinfected with vTF7-3
and the appropriate vaccinia virus recombinant at a multiplicity of
infection of 5 pfu/ml. At 4.5 h postinfection, cells were
pulse-labeled for 10 min. Cell lysates were immunoprecipitated with mab
A4 and samples were analyzed by SDS-PAGE (13%
acrylamide)(a). Bands corresponding to the presence of 1 (1g), 2 (2g), 3 (3g) or 4 (4g) glycans are indicated. Gel autoradiographs were exposed
in the linear range and analyzed by densitometric scanning. The
4-glycan (E1) or 3-glycan (N1, N2, N3, or N4) bands were quantified and
expressed as percent of total or mutant E1 molecules that are fully
glycosylated (b).

View larger version (52K):
[in a new window]
Fig. 4.
Comparison of the glycosylation of E1
expressed alone or coexpressed with E2. a, HepG2 cells
were coinfected with vTF7-3 and the appropriate vaccinia virus
recombinant(s) at a multiplicity of 5 pfu/cell. Infected cells were
harvested at 7-h postinfection, the proteins were separated by SDS-PAGE
(13% acrylamide), and E1 was revealed by Western blotting with the
anti-E1 mab A4. Bands corresponding to the presence of onr
(1g), two (2g), three (3g), or four
(4g) glycans are indicated. b, pulse-chase
analysis of E1 expressed alone or as an E1E2 polyprotein. HepG2 cells
were coinfected with vTF7-3 and the appropriate vaccinia virus
recombinant at a multiplicity of infection of 5 pfu/ml. At 4.5-h
postinfection, cells were pulse-labeled for 5 min and chased for the
indicated times. Cell lysates were immunoprecipitated with mab A4, and
samples were separated by SDS-PAGE (13% acrylamide). Bands
corresponding to the presence of two (2g), three
(3g) or four (4g) glycans are indicated.

View larger version (22K):
[in a new window]
Fig. 5.
Effect of the truncation of E2 on the
glycosylation of E1. HepG2 cells were coinfected with vTF7-3 and
the appropriate vaccinia virus recombinant at a multiplicity of
infection of 5 pfu/ml. At 4.5-h postinfection, cells were pulse-labeled
for 10 min. Cell lysates were immunoprecipitated with mab A4, and
samples were analyzed by SDS-PAGE (13% acrylamide). Quantifications of
fully glycosylated (4g) or partially glycosylated
(<4g) E1 expressed as percent of total E1 are
indicated.

View larger version (74K):
[in a new window]
Fig. 6.
Analysis of intramolecular disulfide bond
formation in E1 expressed as a full-length (E1E2) or a
truncated (E1E2-661) polyprotein or expressed alone
(E1). HepG2 cells were coinfected with vTF7-3 and
the appropriate vaccinia virus recombinant at a multiplicity of
infection of 5 pfu/ml. At 4.5-h postinfection, cells were pulse-labeled
for 5 min and chased for the indicated times. Cell lysates were
immunoprecipitated with mab A4, and immunoprecipitates were analyzed
under nonreducing condition by SDS-PAGE (10% acrylamide).
Red, reduced; ox, oxidized.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
To whom correspondence should be addressed: Equipe Hépatite
C, CNRS-UMR8526, Institut de Biologie de Lille & Institut Pasteur de
Lille, 1 rue Calmette, BP447, 59021 Lille cedex, France. Tel.: 33-3-20-87 11-60; Fax: 33-3-20-87-11-11; E-mail:
jean.dubuisson@ibl.fr.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kornfeld, R.,
and Kornfeld, S.
(1985)
Annu. Rev. Biochem.
54,
631-664
2.
Rademacher, T. W.,
Parekh, R. B.,
and Dwek, R. A.
(1988)
Annu. Rev. Biochem.
57,
785-838
3.
Ellgaard, L.,
Molinari, M.,
and Helenius, A.
(1999)
Science
286,
1882-1888
4.
Trombetta, E. S.,
and Helenius, A.
(1998)
Curr. Opin. Struct. Biol.
8,
587-592
5.
Silberstein, S.,
and Gilmore, R.
(1996)
FASEB J.
10,
849-858
6.
Nilsson, I.,
and von Heijne, G.
(1993)
J. Biol. Chem.
268,
5798-5801
7.
Welply, J. K.,
Shenbagamurthi, P.,
Lennarz, W. J.,
and Naider, F.
(1983)
J. Biol. Chem.
258,
11856-11863
8.
Kelleher, D. J.,
Kreibich, G.,
and Gilmore, R.
(1992)
Cell
69,
55-65
9.
Pless, D. D.,
and Lennarz, W. J.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
134-138
10.
Marshall, R. D.
(1974)
Biochem. Soc. Symp.
40,
17-26
11.
Bause, E.
(1983)
Biochem. J.
209,
331-336
12.
Lehle, L.,
and Bause, E.
(1984)
Biochim. Biophys. Acta
799,
246-251
13.
Imperiali, B.,
and Shannon, K. L.
(1991)
Biochemistry
30,
4374-4380
14.
Gavel, Y.,
and von Heijne, G.
(1990)
Protein Eng.
3,
433-442
15.
Shakin-Eshleman, S. H.,
Remaley, A. T.,
Eshleman, J. R.,
Wunner, W. H.,
and Spitalnik, S. L.
(1992)
J. Biol. Chem.
267,
10690-10698
16.
Shakin-Eshleman, S. H.,
Spitalnik, S. L.,
and Kasturi, L.
(1996)
J. Biol. Chem.
271,
6363-6366
17.
Capellari, S.,
Zaidi, S. I.,
Urig, C. B.,
Perry, G.,
Smith, M. A.,
and Petersen, R. B.
(1999)
J. Biol. Chem.
274,
34846-34850
18.
Allen, S.,
Naim, H. Y.,
and Bulleid, N. J.
(1995)
J. Biol. Chem.
270,
4797-4804
19.
Holst, B.,
Bruun, A. W.,
Kielland-Brandt, M. C.,
and Winther, J. R.
(1996)
EMBO J.
15,
3538-3546
20.
Dubuisson, J.
(2000)
Curr. Top. Microbiol. Immunol.
242,
135-148
21.
Reed, K. E.,
and Rice, C. M.
(1998)
Curr. Stud. Hematol. Blood Transf.
62,
1-37
22.
Meunier, J.-C.,
Fournillier, A.,
Choukhi, A.,
Cahour, A.,
Cocquerel, L.,
Dubuisson, J.,
and Wychowski, C.
(1999)
J. Gen. Virol.
80,
887-896
23.
Kieny, M.-P.,
Lathe, R.,
Drillien, R.,
Spehner, D.,
Skory, S.,
Schmitt, D.,
Wiktor, T.,
Koprowski, H.,
and Lecocq, J.-P.
(1984)
Nature
312,
163-166
24.
Fuerst, T. R.,
Niles, E. G.,
Studier, F. W.,
and Moss, B.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
8122-8126
25.
Fournillier-Jacob, A.,
Cahour, A.,
Escriou, N.,
Girard, M.,
and Wychowski, C.
(1996)
J. Gen. Virol.
77,
1055-1064
26.
Cocquerel, L.,
Wychowski, C.,
Minner, F.,
Penin, F.,
and Dubuisson, J.
(2000)
J. Virol.
74,
3623-3633
27.
Michalak, J.-P.,
Wychowski, C.,
Choukhi, A.,
Meunier, J.-C.,
Ung, S.,
Rice, C. M.,
and Dubuisson, J.
(1997)
J. Gen. Virol.
78,
2299-2306
28.
Dubuisson, J.,
Hsu, H. H.,
Cheung, R. C.,
Greenberg, H. B.,
Russell, D. G.,
and Rice, C. M.
(1994)
J. Virol.
68,
6147-6160
29.
Dubuisson, J.,
and Rice, C. M.
(1996)
J. Virol.
70,
778-786
30.
Rice, C. M.
(1996)
in
Fields Virology
(Fields, B. N.
, Knipe, D. M.
, and Howley, P. M., eds), 3rd Ed.
, pp. 931-959, Lippincott-Raven, Philadelphia, PA
31.
Matsuura, Y.,
Harada, S.,
Suzuki, R.,
Watanabe, Y.,
Inoue, Y.,
Saito, I.,
and Miyamura, T.
(1992)
J. Virol.
66,
1425-1431
32.
Lanford, R. E.,
Notvall, L.,
Chavez, D.,
White, R.,
Frenzel, G.,
Simonsen, C.,
and Kim, J.
(1993)
Virology
197,
225-235
33.
Choukhi, A.,
Ung, S.,
Wychowski, C.,
and Dubuisson, J.
(1998)
J. Virol.
72,
3851-3858
34.
Cocquerel, L.,
Duvet, S.,
Meunier, J.-C.,
Pillez, A.,
Cacan, R.,
Wychowski, C.,
and Dubuisson, J.
(1999)
J. Virol.
73,
2641-2649
35.
Bause, E.,
and Hettkamp, H.
(1979)
FEBS Lett.
108,
341-344
36.
Kaplan, H. A.,
Welply, J. K.,
and Lennarz, W. J.
(1987)
Biochim. Biophys. Acta
906,
161-173
37.
Bulleid, N. J.,
Bassel-Duby, R. S.,
Freedman, R. B.,
Sambrook, J. F.,
and Gething, M. J.
(1992)
Biochem. J.
286,
275-280
38.
Bause, E.,
Hettkamp, H.,
and Legler, G.
(1982)
Biochem. J.
203,
761-768
39.
Mellquist, J. L.,
Kasturi, L.,
Spitalnik, S. L.,
and Shakin-Eshleman, S. H.
(1998)
Biochemistry
37,
6833-6837
40.
Livi, G. P.,
Lillquist, J. S.,
Miles, L. M.,
Ferrara, A.,
Sathe, G. M.,
Simon, P. L.,
Meyers, C. A.,
Gorman, J. A.,
and Young, P. R.
(1991)
J. Biol. Chem.
266,
15348-15355
41.
Schroder, K.,
Martoglio, B.,
Hofmann, M.,
Holscher, C.,
Hartmann, E.,
Prehn, S.,
Rapoport, T. A.,
and Dobberstein, B.
(1999)
EMBO J.
18,
4804-4815
42.
Shakin-Eshleman, S. H.,
Wunner, W. H.,
and Spitalnik, S. L.
(1993)
Biochemistry
32,
9465-9472
43.
Nilsson, I.,
and von Heijne, G.
(2000)
J. Biol. Chem.
275,
17338-17343
44.
Whitley, P.,
Nilsson, I. M.,
and von Heijne, G.
(1996)
J. Biol. Chem.
271,
6241-6244
45.
Imperiali, B.,
Shannon, K. L.,
and Rickert, K. W.
(1992)
J. Amer. Chem. Soc.
114,
7042-7044
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
K. Okamoto, Y. Mori, Y. Komoda, T. Okamoto, M. Okochi, M. Takeda, T. Suzuki, K. Moriishi, and Y. Matsuura Intramembrane Processing by Signal Peptide Peptidase Regulates the Membrane Localization of Hepatitis C Virus Core Protein and Viral Propagation J. Virol., September 1, 2008; 82(17): 8349 - 8361. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Krause, P. Berger, J. Roig, V. Singh, and W. E. Merz Rapid Maturation of Glycoprotein Hormone Free {alpha}-Subunit (GPH{alpha}) and GPH{alpha}{alpha} Homodimers Mol. Endocrinol., October 1, 2007; 21(10): 2551 - 2564. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sandrin, P. Boulanger, F. Penin, C. Granier, F.-L. Cosset, and B. Bartosch Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins J. Gen. Virol., December 1, 2005; 86(12): 3189 - 3199. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Goffard, N. Callens, B. Bartosch, C. Wychowski, F.-L. Cosset, C. Montpellier, and J. Dubuisson Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Glycoproteins J. Virol., July 1, 2005; 79(13): 8400 - 8409. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. V. Svitkin, A. Pause, M. Lopez-Lastra, S. Perreault, and N. Sonenberg Complete Translation of the Hepatitis C Virus Genome In Vitro: Membranes Play a Critical Role in the Maturation of All Virus Proteins except for NS3 J. Virol., June 1, 2005; 79(11): 6868 - 6881. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bolt, C. Kristensen, and T. D. Steenstrup Posttranslational N-glycosylation takes place during the normal processing of human coagulation factor VII Glycobiology, May 1, 2005; 15(5): 541 - 547. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Zhang, B. Gaschen, W. Blay, B. Foley, N. Haigwood, C. Kuiken, and B. Korber Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin Glycobiology, December 1, 2004; 14(12): 1229 - 1246. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Carrere-Kremer, C. Montpellier, L. Lorenzo, B. Brulin, L. Cocquerel, S. Belouzard, F. Penin, and J. Dubuisson Regulation of Hepatitis C Virus Polyprotein Processing by Signal Peptidase Involves Structural Determinants at the p7 Sequence Junctions J. Biol. Chem., October 1, 2004; 279(40): 41384 - 41392. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Okamoto, K. Moriishi, T. Miyamura, and Y. Matsuura Intramembrane Proteolysis and Endoplasmic Reticulum Retention of Hepatitis C Virus Core Protein J. Virol., June 15, 2004; 78(12): 6370 - 6380. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Op De Beeck, C. Voisset, B. Bartosch, Y. Ciczora, L. Cocquerel, Z. Keck, S. Foung, F.-L. Cosset, and J. Dubuisson Characterization of Functional Hepatitis C Virus Envelope Glycoproteins J. Virol., March 15, 2004; 78(6): 2994 - 3002. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dumonceaux, E. G. Cormier, F. Kajumo, G. P. Donovan, J. Roy-Chowdhury, I. J. Fox, J. P. Gardner, and T. Dragic Expression of Unmodified Hepatitis C Virus Envelope Glycoprotein-Coding Sequences Leads to Cryptic Intron Excision and Cell Surface Expression of E1/E2 Heterodimers Comprising Full-Length and Partially Deleted E1 J. Virol., December 15, 2003; 77(24): 13418 - 13424. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-A. Petit, C. Jolivet-Reynaud, E. Peronnet, Y. Michal, and C. Trepo Mapping of a Conformational Epitope Shared between E1 and E2 on the Serum-derived Human Hepatitis C Virus Envelope J. Biol. Chem., November 7, 2003; 278(45): 44385 - 44392. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cocquerel, C.-C. Kuo, J. Dubuisson, and S. Levy CD81-Dependent Binding of Hepatitis C Virus E1E2 Heterodimers J. Virol., October 1, 2003; 77(19): 10677 - 10683. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Cocquerel, E. R. Quinn, M. Flint, K. G. Hadlock, S. K. H. Foung, and S. Levy Recognition of Native Hepatitis C Virus E1E2 Heterodimers by a Human Monoclonal Antibody J. Virol., December 20, 2002; 77(2): 1604 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Anjos, A. Nguyen, H. Ounissi-Benkalha, M.-C. Tessier, and C. Polychronakos A Common Autoimmunity Predisposing Signal Peptide Variant of the Cytotoxic T-lymphocyte Antigen 4 Results in Inefficient Glycosylation of the Susceptibility Allele J. Biol. Chem., November 22, 2002; 277(48): 46478 - 46486. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Carrere-Kremer, C. Montpellier-Pala, L. Cocquerel, C. Wychowski, F. Penin, and J. Dubuisson Subcellular Localization and Topology of the p7 Polypeptide of Hepatitis C Virus J. Virol., March 19, 2002; 76(8): 3720 - 3730. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Tsitoura, M. Lucas, V. Revol-Guyot, A. L. Epstein, R. Manservigi, and P. Mavromara Expression of hepatitis C virus envelope glycoproteins by herpes simplex virus type 1-based amplicon vectors J. Gen. Virol., March 1, 2002; 83(3): 561 - 566. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Duvet, A. Op De Beeck, L. Cocquerel, C. Wychowski, R. Cacan, and J. Dubuisson Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line Glycobiology, February 1, 2002; 12(2): 95 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fournillier, C. Wychowski, D. Boucreux, T. F. Baumert, J.-C. Meunier, D. Jacobs, S. Muguet, E. Depla, and G. Inchauspe Induction of Hepatitis C Virus E1 Envelope Protein-Specific Immune Response Can Be Enhanced by Mutation of N-Glycosylation Sites J. Virol., December 15, 2001; 75(24): 12088 - 12097. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Merola, M. Brazzoli, F. Cocchiarella, J. M. Heile, A. Helenius, A. J. Weiner, M. Houghton, and S. Abrignani Folding of Hepatitis C Virus E1 Glycoprotein in a Cell-Free System J. Virol., November 15, 2001; 75(22): 11205 - 11217. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Op De Beeck, L. Cocquerel, and J. Dubuisson Biogenesis of hepatitis C virus envelope glycoproteins J. Gen. Virol., November 1, 2001; 82(11): 2589 - 2595. [Full Te |